Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Meditation brain study in Parkinson's withdrawn before starting

NCT ID NCT05103618

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study planned to use brain scans to measure how a meditation technique called OM affects dopamine and stress markers in people with Parkinson's disease. It was withdrawn before enrolling any participants, so no results are available. The goal was to better understand meditation's potential impact on brain health in Parkinson's.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OM Meditation (behavioral) and [F-18] Fluorodopa (imaging tracer)

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Started

Jul 2021

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:(Control Group: 6 healthy, normal couple pairs) 1. No clinical diagnosis of PD 2. Age 25 years old and older 3. Physically independent, ambulatory 4. Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception. Inclusion Criteria for Female Partner in Couple Pairs in Parkinson's Group who has Parkinson's Disease 1. Clinical diagnosis of PD in female partner 2. Age 30 years old and older 3. Physically independent, ambulatory 4. Hoehn and Yahr score of I-III inclusive. 5. On stable antiparkinsonian medication for at least one month 6. Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception. Inclusion Criteria for Second Partner with No PD in Couple Pairs in Parkinson's Group 1. No clinical diagnosis of PD 2. Age 25 years old and older 3. Physically independent, ambulatory 4. Women of childbearing potential will confirm a negative pregnancy test and must practice effective contraception during the period of pilot study. In addition, male subjects who have a partner of childbearing age should practice effective contraception. Exclusion Criteria: (In Control Couple Pairs and in Couple Pairs Group in which the Female member has PD) 1. Previous brain surgery. 2. Cognitive impairment by evaluation or known score on Mini-Mental Status examination of 25 or lower. 3. Wheelchair-bound or bed-ridden, non-ambulatory. 4. Intracranial abnormalities that may complicate interpretation of the brain scans (e.g., stroke, tumor, vascular abnormality affecting the target area). 5. Diagnosis of traumatic brain injury with significant impairment. 6. Any medical disorder or physical condition that could reasonably be expected to interfere with the assessment of parkinsonian syndrome symptoms, or with any of the study assessments including the PET-MRI imaging. 7. No metal in their body that would prevent MRI scanning (as determined by the PI). 8. Subjects with evidence of a significant psychiatric disorder by history/examination that would prevent completion of the study will not be allowed to participate. 9. Subjects with current alcohol or drug abuse. 10. Pregnant or lactating women. 11. Enrollment in active clinical trial/ experimental therapy within the prior 30 days. 12. Pending surgery during the course of the study. 13. History of thrombocytopenia or clotting disorders. 14. Cancer patients receiving active chemotherapy. 15. History of uncontrolled diabetes and/or thyroid conditions. 16. History of severe kidney disease (if a subject reports this problem, a serum creatinine will be checked to assess glomerular filtration rate (GFR) and if it is less than 30, they will be excluded).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Idiopathic Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Thomas Jefferson University, Marcus Institute of Integrative Health Centers

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.